Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial
2014 San Antonio Breast Cancer SymposiumHarry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”
Related Videos
Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer
Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09,
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08,
Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer
Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy
Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer
Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02,
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials
Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:
• B-40, the only study to combine neoadjuvant and adjuvant chemoth...
